Hematology News

Patients with graft-versus-host disease who developed steroid-related complications required substantial health care resource utilization and incurred considerable costs, according to results presented at TCT Meetings Digital Experience.

Challenges presented by the COVID-19 pandemic did not stop progress in research or clinical development of gene and cell therapies, according to a state-of-the-industry briefing by Alliance of Regenerative Medicine.

Roswell Park Comprehensive Cancer Center has promoted four physicians to leadership roles in its clinical research program.

Research presented at ASH Annual Meeting and Exposition provided an exciting update on many of the underappreciated clinical manifestations of cold agglutinin disease, as well as data on potential new therapeutic interventions.

The FDA granted accelerated approval to daratumumab plus hyaluronidase-fihj in combination with bortezomib, cyclophosphamide and dexamethasone for treatment of newly diagnosed light chain amyloidosis.

Recruitment for the convalescent plasma arm of the RECOVERY trial was closed after an independent board determined there was no evidence the treatment benefited patients with COVID-19, according to the trial’s chief investigators.

The FDA granted breakthrough therapy designation to avapritinib for treatment of moderate to severe indolent systemic mastocytosis, according to the agent’s manufacturer.

Understanding risk factors for COVID-19 susceptibility and severity has been an ongoing objective of researchers during the pandemic.

Two studies presented at the virtual ASH Annual Meeting and Exposition yielded conflicting results in terms of the effect of anticoagulants on COVID-19 outcomes.

Sickle cell trait was not associated with increased risk for MI or CHD in Black individuals, according to a cohort study published in JAMA Network Open.